409 related articles for article (PubMed ID: 26311249)
41. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
42. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
[TBL] [Abstract][Full Text] [Related]
43. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
44. Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Beier D; Röhrl S; Pillai DR; Schwarz S; Kunz-Schughart LA; Leukel P; Proescholdt M; Brawanski A; Bogdahn U; Trampe-Kieslich A; Giebel B; Wischhusen J; Reifenberger G; Hau P; Beier CP
Cancer Res; 2008 Jul; 68(14):5706-15. PubMed ID: 18632623
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Beier D; Schriefer B; Brawanski K; Hau P; Weis J; Schulz JB; Beier CP
J Neurooncol; 2012 Aug; 109(1):45-52. PubMed ID: 22544650
[TBL] [Abstract][Full Text] [Related]
46. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
47. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Hosein AN; Lim YC; Day B; Stringer B; Rose S; Head R; Cosgrove L; Sminia P; Fay M; Martin JH
J Neurooncol; 2015 Apr; 122(2):263-71. PubMed ID: 25648357
[TBL] [Abstract][Full Text] [Related]
48. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
[TBL] [Abstract][Full Text] [Related]
49. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
Vlachostergios PJ; Hatzidaki E; Papandreou CN
Neurol Res; 2013 Oct; 35(8):879-82. PubMed ID: 23561593
[TBL] [Abstract][Full Text] [Related]
50. Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines.
Kirstein A; Schilling D; Combs SE; Schmid TE
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202589
[TBL] [Abstract][Full Text] [Related]
51. Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Schäfer A; Teufel J; Ringel F; Bettstetter M; Hoepner I; Rasper M; Gempt J; Koeritzer J; Schmidt-Graf F; Meyer B; Beier CP; Schlegel J
Neuro Oncol; 2012 Dec; 14(12):1452-64. PubMed ID: 23132408
[TBL] [Abstract][Full Text] [Related]
52. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Lee DJ; Sharma N; Dubeau L; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2014 Aug; 13(8):2004-17. PubMed ID: 24994771
[TBL] [Abstract][Full Text] [Related]
53. In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma.
Barazzuol L; Jena R; Burnet NG; Jeynes JC; Merchant MJ; Kirkby KJ; Kirkby NF
Radiat Res; 2012 May; 177(5):651-62. PubMed ID: 22468703
[TBL] [Abstract][Full Text] [Related]
54. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
55. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
[TBL] [Abstract][Full Text] [Related]
56. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Xipell E; Aragón T; Martínez-Velez N; Vera B; Idoate MA; Martínez-Irujo JJ; Garzón AG; Gonzalez-Huarriz M; Acanda AM; Jones C; Lang FF; Fueyo J; Gomez-Manzano C; Alonso MM
Neuro Oncol; 2016 Aug; 18(8):1109-19. PubMed ID: 26951384
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
He W; Liu R; Yang SH; Yuan F
Anticancer Drugs; 2015 Mar; 26(3):293-300. PubMed ID: 25535979
[TBL] [Abstract][Full Text] [Related]
58. The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
Kinashi Y; Ikawa T; Takahashi S
Appl Radiat Isot; 2020 Sep; 163():109204. PubMed ID: 32561044
[TBL] [Abstract][Full Text] [Related]
59. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Eich M; Roos WP; Nikolova T; Kaina B
Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
[TBL] [Abstract][Full Text] [Related]
60. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Palmieri D; Duchnowska R; Woditschka S; Hua E; Qian Y; Biernat W; Sosińska-Mielcarek K; Gril B; Stark AM; Hewitt SM; Liewehr DJ; Steinberg SM; Jassem J; Steeg PS
Clin Cancer Res; 2014 May; 20(10):2727-39. PubMed ID: 24634373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
